trial · primary record
ARC-02
B-cell Non Hodgkin Lymphoma
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 140 |
| Primary completion | 2030-12 |
| Primary endpoint | Dose Escalation: Number of Participants with Dose-Limiting Toxicities (DLTs) |
| Registry ID | NCT07691606 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:44:24.975Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07691606
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.